PI3KR1 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P27986 |
---|---|
Clone Names | 2071501 |
Gene ID | 5295 |
---|---|
Other Names | Phosphatidylinositol 3-kinase regulatory subunit alpha, PI3-kinase regulatory subunit alpha, PI3K regulatory subunit alpha, PtdIns-3-kinase regulatory subunit alpha, Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha, PI3-kinase subunit p85-alpha, PtdIns-3-kinase regulatory subunit p85-alpha, PIK3R1, GRB1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP8023a was selected from the N-term region of human PI3KR1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PIK3R1 |
---|---|
Synonyms | GRB1 |
Function | Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348923). |
Tissue Location | Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
PI3KR1 binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the P110 catalytic unit to the plasma membrane. It is necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. It is a component of a heterodimer composed of P110 (catalytic) and P85 (regulatory) subunits. PI3KR1 is proposed to interact with phosphorylated TOM1L1. Defects in PIK3R1 are a cause of severe insulin resistance. The protein contains 1 Rho-GAP domain, 2 SH2 domains, and 1 SH3 domain.
References
Baynes, K.C., et al., Diabetologia 43(3):321-331 (2000).Hansen, T., et al., Diabetes 46(3):494-501 (1997).Musacchio, A., et al., Proc. Natl. Acad. Sci. U.S.A. 93(25):14373-14378 (1996).Nolte, R.T., et al., Nat. Struct. Biol. 3(4):364-374 (1996).Liang, J., et al., J. Mol. Biol. 257(3):632-643 (1996).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.